Cargando…

Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75

Recently emerged SARS-CoV-2 Omicron subvariant, BA.2.75, displayed a growth advantage over circulating BA.2.38, BA.2.76, and BA.5 in India. However, the underlying mechanisms for enhanced infectivity, especially compared with BA.5, remain unclear. Here, we show that BA.2.75 exhibits substantially hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yunlong, Song, Weiliang, Wang, Lei, Liu, Pan, Yue, Can, Jian, Fanchong, Yu, Yuanling, Yisimayi, Ayijiang, Wang, Peng, Wang, Yao, Zhu, Qianhui, Deng, Jie, Fu, Wangjun, Yu, Lingling, Zhang, Na, Wang, Jing, Xiao, Tianhe, An, Ran, Liu, Lu, Yang, Sijie, Niu, Xiao, Gu, Qingqing, Shao, Fei, Hao, Xiaohua, Meng, Bo, Gupta, Ravindra Kumar, Jin, Ronghua, Wang, Youchun, Xie, Xiaoliang Sunney, Wang, Xiangxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531665/
https://www.ncbi.nlm.nih.gov/pubmed/36270286
http://dx.doi.org/10.1016/j.chom.2022.09.018
Descripción
Sumario:Recently emerged SARS-CoV-2 Omicron subvariant, BA.2.75, displayed a growth advantage over circulating BA.2.38, BA.2.76, and BA.5 in India. However, the underlying mechanisms for enhanced infectivity, especially compared with BA.5, remain unclear. Here, we show that BA.2.75 exhibits substantially higher affinity for host receptor angiotensin-converting enzyme 2 (ACE2) than BA.5 and other variants. Structural analyses of BA.2.75 spike shows its decreased thermostability and increased frequency of the receptor binding domain (RBD) in the “up” conformation under acidic conditions, suggesting enhanced low-pH-endosomal cell entry. Relative to BA.4/BA.5, BA.2.75 exhibits reduced evasion of humoral immunity from BA.1/BA.2 breakthrough-infection convalescent plasma but greater evasion of Delta breakthrough-infection convalescent plasma. BA.5 breakthrough-infection plasma also exhibits weaker neutralization against BA.2.75 than BA.5, mainly due to BA.2.75’s distinct neutralizing antibody (NAb) escape pattern. Antibody therapeutics Evusheld and Bebtelovimab remain effective against BA.2.75. These results suggest BA.2.75 may prevail after BA.4/BA.5, and its increased receptor-binding capability could support further immune-evasive mutations.